Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

InforSense Partners with U.K.’s Leading Institutions to Combat Alzheimer’s Disease

Published: Wednesday, December 03, 2008
Last Updated: Wednesday, December 03, 2008
Bookmark and Share
Translational research solution to help accelerate early diagnosis and personalized medicine treatments.

InforSense Ltd. has announced that the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at the South London and Maudsley National Health Service (NHS) Foundation Trust (SLaM) and Institute of Psychiatry, King’s College London will use InforSense’s translational research solutions in Alzheimer’s disease studies to advance the development of early diagnostic tools and develop personalized medicine treatments within mental health research.

For the first time, informaticians, researchers and clinicians will be able to directly access their entire patient and ‘omics’ data  through a common data analysis platform. The InforSense solution will eliminate errors associated with manual data processes and bottlenecks relating to data access and analysis by non specialist end users.

“Our research centers on understanding the molecular and cellular events that take place in the brain in Alzheimer’s disease and in particular we are working on blood based biomarkers to aid early diagnosis,” said Simon Lovestone, Professor of Old Age Psychiatry at King’s College London and Director of the Biomedical Research Centre for Mental Health.

“The translational solutions that InforSense provides will enable us to have an integrated data set under a common system that informaticians, researchers and clinicians can all use to access and analyze data. This will result in improved data sharing and removal of access bottlenecks, speeding up the speed and accuracy of novel biomarker identification.”

Translational research is the practice of linking clinical and research data to identify early diagnostics, also known as biomarkers, improve disease understanding and ultimately enhance patient care.

The InforSense Translational Research solution, including the InforSense platform, ClinicalSense, GenSense, and BioSense, will be used by the Biomedical Research Centre for Mental Health to integrate and analyze patient, genotyping, transcriptomics, proteomics and MRI data to support the identification of biomarkers. Researchers will also be able to access and analyze data using the VisualSense interactive web portal.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

InforSense GenSense Achieves GeneChip-compatible™ Status with the Affymetrix GeneChip® Microarray Platform
Affymetrix has become a member of InforSense’s Open Workflow Partner Network joining over 40 other partners in the program.
Tuesday, August 07, 2007
InforSense® Announces Conference Series
The InforSense Users Conference will provide opportunity to learn how InforSense KDE is being used to facilitate business-critical decision-making across a variety of industries.
Tuesday, November 14, 2006
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Discovering the First Farmers
Genetic analyses reveal a collection of highly distinct groups in the Near East and Europe at the dawn of agriculture.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!